Evidence map›Paper›PMID 40379854›Full record

ArticleSurgical endoscopy2025

Liver resection versus interventional treatments for hepatocellular carcinoma patients with hypohepatia: a multicenter study.

Shoujie Zhao, Yejing Zhu, Jinming Zhu, Bo Wang, Enxin Wang, Jun Zhu, Liangzhi Wen, Yan Zhao, Man Yang, Luo Zuo and 9 more

Abstract readMulticenter StudyComparative Study
In one paragraph

Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Shoujie Zhao *State Key Laboratory of Holistic Intergrative Management of Gastrointestinal Cancers and Xijng Hospital of Digestive Diseases, Fourth Military Medical University, No. 127 Changlexi Road, Xi'an, 710032, China.
Yejing Zhu *Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Jinming Zhu *Department of General Surgery, The 960th Hospital of the PLA Joint Logistics Support Force, Shandong Provincial Key Medical and Health Discipline of Chinese PLA 960 Hospital, Ji'nan, China.
Bo WangDepartment of General Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Enxin WangDepartment of Digestive Diseases, Air Force Hospital of Western Theater Command, Chengdu, China.
Jun ZhuDepartment of General Surgery, Air Force Hospital of Southern Theater Command, Guangzhou, China.
Liangzhi WenDepartment of Gastroenterology, Daping Hospital, Third Military Medical University, Chongqing, China.
Yan ZhaoDepartment of Digestive Diseases, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China.
Man YangDepartment of Digestive Disease, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Luo ZuoDepartment of Digestive Diseases, The Second Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Jiahao FanDepartment of Digestive Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Jia JiaDepartment of Emergency, Shaanxi Provincial People's Hospital, Xi'an, China.
Wenbing WuDepartment of Digestive Diseases, Xi'an First Hospital, Xi'an, China.
Weirong RenDepartment of Digestive Diseases, Sanmenxia Central Hospital, Henan University of Science and Technology, Sanmenxia, China.
Xing ChenDepartment of Oncology, Qingdao Women and Children's Hospital, Qingdao, China.
Jing LiDepartment of Digestive Diseases, Shanxi Bethune Hospital, Shanxi Academy of Medical Science, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.
Xingshun QiDepartment of Digestive Diseases, General Hospital of Northern Theater Command, Shenyang, China.
Xilin DuDepartment of General Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Lei LiuState Key Laboratory of Holistic Intergrative Management of Gastrointestinal Cancers and Xijng Hospital of Digestive Diseases, Fourth Military Medical University, No. 127 Changlexi Road, Xi'an, 710032, China. liulei84207@163.com.

Funding

National Natural Science Foundation of China 82173143National Natural Science Foundation of China 82373409Shaanxi Outstanding Youth Science Fund Project 2024JC-JCQN-78Special Project for Clinical Research of Xijing Hospital Boosting Project XJZT24LY30
6 · The paper itself

Abstract

backgroundHypohepatia limits the feasibility of therapeutic options for hepatocellular carcinoma (HCC), negatively affecting patient prognosis. Established guidelines for the treatment strategies of HCC patients with hypohepatia are lacking. This study was performed to evaluate therapeutic benefits between liver resection (LR) and interventional treatments using ablation or transarterial chemoembolization (TACE) in such population.

methodsSurvival analyses were performed using the Kaplan-Meier method and log-rank test. The Cox proportional hazards regression models were used to analyze potential risk factors associated with prognosis. Multivariate regression and propensity score regression adjustment analyses were applied to adjust for baseline confounding variables. Restricted cubic spline curves were used to assess the association between prognostic index and risk of death or progression on a continuous scale.

resultsOf the enrolled 5774 HCC patients with hypohepatia, 506 (8.8%), 2326 (40.3%) and 2942 (51.0%) underwent ablation, LR and TACE, respectively. A tentative analysis of the overall cohort demonstrated that a high degree of heterogeneity existed in this population, while LR rendered a possible tendency to survival benefit over ablation and TACE through adjustment for baseline confounding variables. After categorizing the patients according to the indication of ablation treatment, the indisputable superiority of LR over ablation and TACE in terms of OS and DFS before and after adjustments were evident and the survival advantages of LR were consistent across all pre-specified subgroups. Individualized treatment decision analyses based on restricted cubic spline curves demonstrated that LR group presented the lowest risk of death and disease progression.

conclusionsHCC patients with hypohepatia could obtain survival benefits through surgical and non-surgical treatment approaches. LR appears to confer a significant survival benefit compared with interventional treatments using ablation or TACE, even for selected intermediate and advanced populations.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticHepatectomyLiver NeoplasmsAgedFemaleHumansMaleMiddle AgedPropensity ScoreRetrospective StudiesTreatment OutcomeHepatocellular carcinomaHypohepatiaInterventional treatmentLiver resectionSurvival benefit

Identifiers

PMID40379854
PMCPMC12222368

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.